Proteomics: Clinical applications for head and neck squamous cell carcinoma

Head and Neck

Volumn 28, Issue 6, 2006, Pages 549-558

  Yarbrough, Wendell G ^a,b   Slebos, Robbert J C ^a,b   Liebler, Daniel ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Head and neck cancer; MALDI; Proteomics; SELDI; Squamous cell

Indexed keywords

PROTEOME;

CANCER INVASION; CANCER RESISTANCE; CARCINOGENESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE SEQUENCE; GENOMICS; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METASTASIS; PATIENT CARE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEOMICS; REVIEW; SQUAMOUS CELL CARCINOMA; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY; TECHNOLOGY;

CARCINOMA, SQUAMOUS CELL; CHROMATOGRAPHY, LIQUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEAD AND NECK NEOPLASMS; HUMANS; MASS SPECTROMETRY; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 33744899334     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20357     Document Type: Review

References (22)

1. Chung CH, Parker JS, Karaca G, Wu J, Funkhouser WK, Moore D, Butterfoss D, Xiang D, Zanation A, Yin X, Shockley WW, Weissler MC, Dressier LG, Shores CG, Yarbrough WG, Perou CM. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 2004;5:489-500.
2. Ginos MA, Page GP, Michalowicz BS, Patel KJ, Volker SE, Pambuccian SE, Ondrey FG, Adams GL, Gaffney PM. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res 2004;64:55-63.
3. Ambrosch P, Bricbeck U. Detection of nodal micrometastases in head and neck cancer by serial sectioning and immunostaining. Oncology 1996;10:1221-1226.
4. Becker MT, Shores CG, Yu KK, Yarbrough WG. Molecular assay to detect metastatic head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2004;130:21-27.
5. Coatesworth AP, MacLennan K. Squamous cell carcinoma of the upper aerodigestive tract: the prevalence of microscopic extracapsular spread and soft tissue deposits in the clinically NO neck. Head Neck 2002;24:258-261.
6. Ferlito A, Shaha AR, Rinaldo A. The incidence of lymph node micrometastases in patients with pathologically staged NO in cancer of oral cavity and oropharynx. Oral Oncol 2002;38:3-5.
7. Bernier J, Domenge C, Ozsahin M, Matuszweska K, Lefebvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourshis J, Kirkpatrick A, van Glabbeke M. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945-1952.
8. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1937-1944.
9. Diamandis E. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004;96:353-356.
10. Gao J, Opiteck GJ, Friedrichs MS, Dongre AR, Hefta SA. Changes in the protein expression of yeast as a function of carbon source. J Proteome Res 2003;2:643-649.
11. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-577.
12. Petricoin EF III, Orstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, Velassco A, Trucco C, Wiegand L, Wood K, Simone CB, Levine PJ, Linehan WM, Emmert-Buck MR, Steinberg SM, Kohn EC, Liotta LA. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002;94:1576-1578.
13. Adam B-L, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, Wright GL Jr. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62:3609-3614.
14. Qu Y, Adam B-L, Yasui Y, Ward MD, Cazares LH, Schellhammer PF, Feng Z, Semmes OJ, Wright GL Jr. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002;48:1835-1843.
15. Diamandis E. Point: proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 2003;49:1272-1275.
16. Sorace J, Zhan M. A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinformatics 2003;4. Available at http://www.biomedcentral.com/1471-2105/4/24.
17. Sidransky D, Irizarry R, Califano JA, Li X, Ren H, Benoit N, Mao L. Serum protein MALDI profiling to distinguish upper aerodigestive tract cancer patients from control subjects. J Natl Cancer Inst 2003;95:1711-1717.
18. Wadsworth JT, Somers KD, Stack BC Jr, Cazares L, Malik G, Adam B-L, Wright GL Jr, Semmes OJ. Identification of patients with head and neck cancer using serum protein profiles. Arch Otolaryngol Head Neck Surg 2004;130:98-104.
19. Soltys SG, Le QT, Shi G, Tibshirani R, Giaccia AJ, Koong AC. The use of plasma surface-enhanced laser desorption/ionization time-of-flight mass spectrometry proteomic patterns for detection of head and neck squamous cell cancers. Clin Cancer Res 2004;10:4806-4812.
20. Yanagisawa K, Shyr Y, Xu BJ, Massion PP, Larsen PH, White BC, Roberts JR, Edgerton M, Gonzalez A, Nadaf S. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 2003;362:433-439.
21. Tuma R. A big trial for a new technology: Trans BIG project takes microarrays into clinical trials. J Natl Cancer Inst 2004;96:648-649.
22. Lynch TJ, Bell DW, Sordella R, Gurubhagaatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.